Advertisement
YOU ARE HERE: LAT HomeCollectionsAlzheimer S Disease
IN THE NEWS

Alzheimer S Disease

NEWS
July 23, 1994 | THOMAS H. MAUGH II, TIMES MEDICAL WRITER
People with below-average head size have as much as 18 times the normal risk of developing dementia caused by Alzheimer's and other diseases, Washington state researchers have found. The findings suggest that such individuals do not have enough brain cells in reserve to offset the loss of cells caused by aging and neurological diseases, said epidemiologist Amy B. Graves of Battelle Pacific Northwest Laboratories in Seattle.
Advertisement
CALIFORNIA | LOCAL
December 26, 1988 | MARGIE PATLAK, Patlack is a free-lance writer based in Whitefish Bay, Wis
Scientists using new computer technologies are gaining insight into the three-dimensional structure of some of the body's key proteins. At the forefront of this new frontier is one of these proteins--the enzyme superoxide dismutase (SOD), famous for preventing oxygen toxicity in the body and thought to hamper such diverse disorders as heart disease, cancer, Alzheimer's disease and the aging process. The scientists have already uncovered a complex scenario in which the enzyme lures and traps the superoxide molecule, which it is programmed to destroy.
OPINION
November 21, 2011
There's one thing that all Alzheimer's researchers agree on: The mind-robbing illness is heartbreaking. But after three decades of study that have produced neither cure nor medications that significantly slow its progress, some researchers are asking: What if it's not a disease with a cure? What if it's just an unfortunate but inevitable part of aging, along with wrinkly skin, osteoporosis and heart disease? In a study in the December issue of the Journal of Alzheimer's Disease, a research group led by Dr. Ming Chen at the University of South Florida suggests that "tremendous social pressures" have pushed scientists to target Alzheimer's as a curable disease.
NEWS
March 15, 2013 | By Melissa Healy
Experimental drug treatments promising to slow or reverse the progression of Alzheimer's disease will need to be assessed with a new and more subtle set of rules, a pair of FDA officials wrote this week. The resulting new guidelines, predict some researchers, should allow Alzheimer's drugs under development to travel a faster path to the U.S. market -- and to the more than 5 million Americans who need them. The new guidelines, issued to drug developers last month and outlined this week in the New England Journal of Medicine, reflect a growing shift among both physicians and researchers toward earlier detection and treatment of the memory-robbing disease.
CALIFORNIA | LOCAL
November 25, 1999
Molecular biologists have created a strain of mice that models one of the key features of Alzheimer's disease, the accumulation of "tangles" containing a protein called tau. The tangles, along with another deposit called plaque, are one of the key features of the disease, which affects as many as 4 million Americans. A team from the University of Pennsylvania reports in the November issue of Neuron that it added an extra copy of the tau gene to mice.
SCIENCE
December 10, 2005 | From Times Staff and Wire Reports
The diabetes drug Avandia can enhance memory in patients with mild Alzheimer's disease, but only in patients with a certain genetic profile, researchers from GlaxoSmithKline reported Wednesday at a UC San Diego meeting. The finding supports the hypothesis that impaired glucose metabolism may play a role in the onset of the disorder. The study, using about 500 patients, showed that the drug worked only in patients who did not have a gene variant known as ApoE4.
HEALTH
January 31, 2005 | From Reuters
People who have high blood pressure, cholesterol, diabetes or who smoke in midlife have a much higher risk of developing Alzheimer's disease later on, U.S. researchers have found. And the more factors a person has, the higher the risk. People with all four risk factors have more than double the risk of Alzheimer's, reported a team at Kaiser Permanente's division of research in Oakland. "The message is that the risk factors that are bad for the heart are bad for the brain," said Dr.
NATIONAL
September 5, 2002 | From Times Wire Reports
A government-sponsored trial aimed at seeing if painkillers can reduce the risk of Alzheimer's disease is not only useless, but dangerous and should be stopped, Public Citizen said. The consumer group, which has lobbied against certain diet pills and other drugs, said the study is using the wrong drugs.
NEWS
August 6, 1998 | DENNIS McLELLAN, TIMES STAFF WRITER
Seated in her recliner in the family room of the Long Beach duplex she shares with her identical twin, 87-year-old Ilene Eddy is reminiscing about their childhood back on the family farm in Iowa. At least she's trying to. Her twin, Irene Peterson, a few feet away in her own recliner with its matching floral chair cover, keeps interrupting. "Irene, be quiet, please!" Ilene says. "I'm trying to give information here."
Los Angeles Times Articles
|